Epidemiological Registry Describing Treatment Reality and Therapy Modalities of Patients With Lung Cancer (NSCLC, SCLC and Neuroendocrine Tumors) Requiring Therapy

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
iOMEDICO AG
ClinicalTrials.gov Identifier:
NCT01192919
First received: August 30, 2010
Last updated: February 27, 2014
Last verified: February 2014
  Purpose

Overview of actually used therapy forms in patients with bronchial carcinoma requiring treatment.


Condition
Observational Study
Registry

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Epidemiological Registry Describing Treatment Reality and Therapy Modalities of Patients With Lung Cancer (NSCLC, SCLC and Neuroendocrine Tumors) Requiring Therapy.

Resource links provided by NLM:


Further study details as provided by iOMEDICO AG:

Primary Outcome Measures:
  • Documentation of actually used therapy forms in bronchial carcinoma requiring treatment [ Time Frame: 3 years per patient ] [ Designated as safety issue: No ]

Estimated Enrollment: 2500
Study Start Date: January 2010
Estimated Study Completion Date: September 2016
Estimated Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts
Patients with lung cancer
Patients with lung cancer requiring therapy

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients with lung cancer requiring therapy

Criteria

Inclusion Criteria:

  • all patients suffering from Small Cell Lung Cancer (SCLC), Non Small Lung Cancer (NSCLC) or neuroendocrine tumors receiving therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01192919

Locations
Germany
Germany Multiple Sites All Over Germany Recruiting Multiple Sites, Germany Contact: iOMEDICO AG
Freiburg, Germany, 79108
Sponsors and Collaborators
iOMEDICO AG
Investigators
Principal Investigator: Hans-Werner Tessen, MD
  More Information

No publications provided

Responsible Party: iOMEDICO AG
ClinicalTrials.gov Identifier: NCT01192919     History of Changes
Other Study ID Numbers: IOM TLK
Study First Received: August 30, 2010
Last Updated: February 27, 2014
Health Authority: Germany: Ethics Commission

Keywords provided by iOMEDICO AG:
bronchial carcinoma
progression free survival
registry
therapy-reality
observation
therapy sequences
NSCLC
SCLC
Germany
Erlotinib
Bevacizumab
Pemetrexed

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors

ClinicalTrials.gov processed this record on October 29, 2014